Patient Support for Moderate to Severe Plaque PsO

Ask your TREMFYA^® Sales Representative for additional information and details.

A Professional Sample.
Trial program choice is at the prescriber’s discretion

At the core of the program is a TREMFYA withMe Guide, a dedicated and qualified healthcare professional* who can work one-on-one with patients

VIEW DETAILS

^*Guides do not provide medical advice.

You have options to complete and submit prior authorizations how you prefer.

Prior authorization support for TREMFYA^®

VIEW DETAILS

TREMFYA withMe can provide information and resources on the prior authorization (PA) process to help your patients get started on their prescribed Janssen medication.

VIEW DETAILS

^†CoverMyMeds does not fill out any information that requires the medical judgment of the prescriber, and only the prescriber can determine whether to submit a prior authorization for a determination.

For commercially insured patients:

If Prior Authorization is approved:

TREMFYA withMe Savings Program can help eligible patients save on their out-of-pocket medication costs for TREMFYA^®. Depending on their health insurance plan, savings may apply toward co-pay, co-insurance, or deductible.

VIEW DETAILS

If commercial insurance coverage is delayed >5 business days or denied:

TREMFYA withMe Delay and Denial Support offers eligible patients TREMFYA^® at no cost until their commercial insurance covers the medication. See program requirements.

VIEW DETAILS

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA^®

Ask your TREMFYA^® Sales Representative for additional information and details.

You have options to complete and submit prior authorizations how you prefer.

For commercially insured patients:

If Prior Authorization is approved:

If commercial insurance coverage is delayed >5 business days or denied:

IMPORTANT SAFETY INFORMATION

INDICATIONS

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA®

Ask your TREMFYA® Sales Representative for additional information and details.

You have options to complete and submit prior authorizations how you prefer.

For commercially insured patients:

If Prior Authorization is approved:

If commercial insurance coverage is delayed >5 business days or denied:

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA^®

Ask your TREMFYA^® Sales Representative for additional information and details.